Overview
Overview
Hepatic progenitor cells differentiated from UCT-WJ-MSCs; expressing liver-specific markers and capable of giving rise to hepatocytes and cholangiocytes for liver regeneration
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via hepatic differentiation |
| Activin-A (definitive endoderm) → FGF-4 BMP-2 (hepatic specification) → HGF dexamethasone oncostatin M (hepatocyte maturation) |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: AFP⁺ (α-fetoprotein, early; absent at maturity), ALB⁺ (albumin), HNF4α⁺, CK18⁺, CK19⁺ (cholangiocyte-competent), EpCAM⁺, CD133⁺ |
| Albumin ELISA and urea synthesis assay confirm hepatocyte functional competence |
| Non-tumorigenic (no teratoma risk from UCT-MSC origin vs iPSC/ESC sources) |
Clinical Overview
Clinical Overview
Liver disease encompasses cirrhosis, acute liver failure, NASH, autoimmune hepatitis, and metabolic liver disorders — affecting over 2 billion people globally. Liver transplantation remains the only curative option for advanced disease, but donor scarcity, immunosuppression requirements, and surgical risks severely limit access. Akira Hepatic Stem Cells provide an off-the-shelf, immune-privileged hepatocyte-progenitor replacement therapy. Derived from UCT-WJ-MSCs, they carry the critical advantage of being non-tumorigenic (unlike ESC or iPSC-derived hepatocytes, which risk teratoma formation). In preclinical models, these cells engraft in damaged liver tissue, restore albumin production, reduce bilirubin, improve PT/INR, and dramatically reduce fibrosis through HGF-driven anti-fibrotic signaling. Exosomal cargo (miR-122, HGF, FGF-7) from Akira Hepatic Cells provides a cell-free liver regeneration option via the corresponding exosome product.
Process
Mechanism of Action
Hepatocyte Differentiation & Engraftment: ALB+/HNF4α+ hepatocytes engraft in the space of Disse, establish gap junctions with host hepatocytes (connexin-32), and restore metabolic liver functions including albumin synthesis, urea cycle activity, CYP450 enzyme function, and bile acid conjugation.
Anti-Fibrotic Paracrine Action: HGF secretion is the primary anti-fibrotic mechanism — binding Met receptor on hepatic stellate cells (HSCs), suppressing TGF-β1-driven HSC activation, inducing HSC apoptosis via Fas pathway, and activating MMP-9 for collagen degradation. miR-122 delivery suppresses CTGF and TGF-β1 pro-fibrotic pathways.
Immunomodulation of Hepatic Inflammation: IL-10, IDO, and TGF-β secretion modulates Kupffer cell (liver macrophage) activation, suppressing TNF-α, IL-1β, and IL-6 — the cytokines driving hepatocyte apoptosis in autoimmune hepatitis and alcoholic liver disease.
Cholangiocyte Competency: CK19+/EpCAM+ biliary progenitor derivatives address cholestatic diseases including primary biliary cholangitis and primary sclerosing cholangitis by restoring biliary epithelium integrity.
Metabolic Function Restoration: CYP2D6, CYP3A4, and other drug-metabolizing enzyme expression in mature derivatives supports bioartificial liver device applications and potential bridging therapy for acute liver failure awaiting transplant.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| HNF4α (Hepatocyte Nuclear Factor 4α) | Master hepatocyte transcription factor; albumin, CYP gene regulation |
| Albumin (ALB) | Hepatocyte functional marker and secretory product |
| CK18 / CK19 | Hepatocyte/cholangiocyte cytoskeletal markers |
| EpCAM / CD133 | Hepatic progenitor surface markers; biliary competency |
| miR-122 | Liver-specific miRNA; anti-fibrotic, hepatocyte repair, lipid metabolism |
| HGF (Hepatocyte Growth Factor) | Primary pro-regenerative and anti-fibrotic factor; Met receptor activation |
| FGF-7 / BMP-2 | Hepatic specification factors; continued paracrine hepatotrophic effects |
| IL-10 / IDO | Immunomodulation of Kupffer cells and hepatic inflammatory cascade |
Applications
Therapeutic Applications
- Cirrhosis (all etiologies) — fibrosis reversal, hepatocyte regeneration
- Acute Liver Failure (acetaminophen, viral, ischemic) — bridging to transplant or recovery
- Non-Alcoholic Steatohepatitis (NASH/NAFLD) — steatosis reduction, anti-fibrotic
- Chronic Hepatitis B/C (refractory) — hepatocyte replacement immune regulation
- Autoimmune Hepatitis — T-reg expansion, hepatocyte protection
- Primary Biliary Cholangitis / PSC — biliary epithelium restoration
- Hemochromatosis / Wilson Disease — metabolic correction support
- Post-Hepatectomy Liver Regeneration — accelerated volumetric recovery
- Bioartificial Liver Device (BAL) — ex vivo detoxification during acute failure
Evidence
Clinical & Preclinical Evidence
Preclinical studies using UCT-MSC-derived hepatocytes showed significant improvements in liver function markers in CCl4-induced cirrhosis models: ALT/AST normalized by 65–70% at 4 weeks, serum albumin rose from 1.8 to 3.1 g/dL (normal 3.5–5.0 g/dL), PT shortened from 2.1× to 1.3× normal, and Metavir fibrosis score reduced from F3 to F2 on histological assessment.
The non-tumorigenicity of UCT-MSC-derived hepatic stem cells is a key safety advantage confirmed by subcutaneous injection studies in immunocompromised mice showing no teratoma formation at 12 weeks — contrasting with iPSC-derived hepatocytes that require extensive safety screening due to residual pluripotency risk.[1]
In acute liver failure (ALF) models (D-galactosamine), portal vein injection of hepatic progenitors derived from UCT-MSCs improved 5-day survival from 20% to 65%, reduced serum bilirubin by 75%, and reduced hepatic necrosis area by 60% on histological examination.
A 2024 meta-analysis of MSC therapy in liver disease across 15 RCTs (covering cirrhosis, ALF, and NASH) confirmed significant improvements in MELD score (mean reduction 2.8 points), Child-Pugh score, and quality of life markers — with UCT-derived MSCs showing the most consistent outcomes among all MSC sources tested.[2]
The hepatic exosome product (Akira Hepatic Exosomes) derived from these cells carries miR-122, HGF, FGF-7, and anti-fibrotic factors confirmed to promote liver cell regeneration and reduce scarring in preclinical models, extending the cell product's mechanism into a cell-free delivery format.[3]